Immunome, Inc. (IMNM)

Immunome Statistics

Total Valuation

Immunome has a market cap or net worth of $778.47 million. The enterprise value is $541.06 million.

Market Cap	778.47M
Enterprise Value	541.06M

Important Dates

The next estimated earnings date is Thursday, March 27, 2025, after market close.

Earnings Date	Mar 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunome has 81.77 million shares outstanding. The number of shares has increased by 340.37% in one year.

Current Share Class	81.77M
Shares Outstanding	81.77M
Shares Change (YoY)	+340.37%
Shares Change (QoQ)	+0.45%
Owned by Insiders (%)	3.50%
Owned by Institutions (%)	58.01%
Float	62.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	50.40
Forward PS	n/a
PB Ratio	2.68
P/TBV Ratio	3.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	53.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.01.

Current Ratio	6.17
Quick Ratio	6.07
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -276.36% and return on invested capital (ROIC) is -62.32%.

Return on Equity (ROE)	-276.36%
Return on Assets (ROA)	-39.89%
Return on Invested Capital (ROIC)	-62.32%
Return on Capital Employed (ROCE)	-51.39%
Revenue Per Employee	$184,164
Profits Per Employee	-$5.55M
Employee Count	55
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.61% in the last 52 weeks. The beta is 1.90, so Immunome's price volatility has been higher than the market average.

Beta (5Y)	1.90
52-Week Price Change	-58.61%
50-Day Moving Average	10.86
200-Day Moving Average	12.90
Relative Strength Index (RSI)	40.67
Average Volume (20 Days)	1,174,713

Short Selling Information

The latest short interest is 9.07 million, so 11.09% of the outstanding shares have been sold short.

Short Interest	9.07M
Short Previous Month	10.54M
Short % of Shares Out	11.09%
Short % of Float	14.58%
Short Ratio (days to cover)	9.10

Income Statement

In the last 12 months, Immunome had revenue of $10.13 million and -$305.35 million in losses. Loss per share was -$5.69.

Revenue	10.13M
Gross Profit	-81.00M
Operating Income	-111.71M
Pretax Income	-232.03M
Net Income	-305.35M
EBITDA	-110.44M
EBIT	-111.71M
Loss Per Share	-$5.69

Balance Sheet

The company has $240.13 million in cash and $2.72 million in debt, giving a net cash position of $237.41 million or $2.90 per share.

Cash & Cash Equivalents	240.13M
Total Debt	2.72M
Net Cash	237.41M
Net Cash Per Share	$2.90
Equity (Book Value)	214.91M
Book Value Per Share	3.56
Working Capital	204.51M

Cash Flow

In the last 12 months, operating cash flow was -$86.19 million and capital expenditures -$52.48 million, giving a free cash flow of -$138.68 million.

Operating Cash Flow	-86.19M
Capital Expenditures	-52.48M
Free Cash Flow	-138.68M
FCF Per Share	-$1.70

Margins

Gross Margin	n/a
Operating Margin	-1,102.86%
Pretax Margin	-3,014.59%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-340.37%
Shareholder Yield	-340.37%
Earnings Yield	-39.22%
FCF Yield	-17.81%

Analyst Forecast

The average price target for Immunome is $28.60, which is 200.42% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.60
Price Target Difference	200.42%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	70.71%
EPS Growth Forecast (5Y)	-54.00%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunome has an Altman Z-Score of 8.55 and a Piotroski F-Score of 2.

Altman Z-Score	8.55
Piotroski F-Score	2